Akeso / 康方生物

Akeso / 康方生物 is the Chinese biotech company used in vol.117.生物医药的2025：抄底中国、研发焦虑和新王继位 as the episode’s clearest example of a Chinese clinical asset changing global pharma behavior. The source focuses on its [[PD1VEGFBispecific|PD-1/VEGF bispecific]] readout and the way [[Merck|默沙东]] publicly asked for longer survival evidence while later moving to buy a related Chinese asset.

The page is source-scoped. It records the episode’s interpretation that Akeso made Chinese innovation-drug capability harder for multinational pharma to dismiss, not an independent assessment of the company’s full pipeline or valuation.

Key Claims

• The episode says Akeso’s PD-1/VEGF bispecific produced strong Chinese phase-3 data, with PFS described by the guest as roughly doubling versus [[Keytruda|K药]] in that context.
• The mechanism is treated as not fully explained: same-molecule dual targeting and tumor-local concentration are offered as possible reasons, not settled biology.
• Akeso anchors the source’s China Biotech Asset Repricing and Multinational Pharma Patent-Cliff Anxiety examples because Chinese data can force defensive global BD action.

Connections

• PD-1/VEGF Bispecific - main technical asset frame.
• Merck / 默沙东 and Keytruda / K药 - global comparator and patent-cliff context in the episode.
• China Biotech Asset Repricing and Biotech License-Out Arbitrage - transaction and valuation context.